OmniAb, Inc. (OABI) Dividend History

OmniAb, Inc. is a biotechnology company focused on developing and licensing innovative antibody discovery platforms. The company’s technology enables the creation of next-generation therapeutic antibodies, primarily serving the biopharmaceutical industry in drug discovery and development.

5980 Horton Street, Emeryville, CA, 94608
Phone: 510-250-7800
Website:

Dividend History

OmniAb, Inc. currently does not pay dividends

Company News

  • VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

    VERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.

    GlobeNewswire Inc.
    Featured Companies: VACH
  • USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates

    USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: USNA
  • Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying

    Although U.S. stocks closed lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Hallador Energy The Trade: Hallador Energy Company (NASDAQ: HNRG) Director Charles Ray Wesley IV

    Benzinga
    Featured Companies: HNRG PPBI
  • Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates

    Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: PSTV
  • Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

    Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: KPTI
Dividend data last updated 06/07/2025 05:13:29 UTC